Literature DB >> 17047117

Anti-TNF-alpha for treatment of amyloidosis associated with Crohn's disease.

A Fernández-Nebro, I Ureña, M V Irigoyen, R García-Vicuña.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17047117      PMCID： PMC1860098     

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


× No keyword cloud information.
  3 in total

1.  Treatment of the nephrotic syndrome with etanercept in patients with the tumor necrosis factor receptor-associated periodic syndrome.

Authors:  E Drewe; E M McDermott; R J Powell
Journal:  N Engl J Med       Date:  2000-10-05       Impact factor: 91.245

2.  Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists.

Authors:  Antonio Fernández-Nebro; Eva Tomero; Vera Ortiz-Santamaría; María Carmen Castro; Alejandro Olivé; Manuel de Haro; Rosa García Portales; Rosa García-Vicuña; María Victoria González-Mari; Armando Laffón; Rosario García-Vicuña
Journal:  Am J Med       Date:  2005-05       Impact factor: 4.965

3.  Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial.

Authors:  W J Sandborn; S B Hanauer; S Katz; M Safdi; D G Wolf; R D Baerg; W J Tremaine; T Johnson; N N Diehl; A R Zinsmeister
Journal:  Gastroenterology       Date:  2001-11       Impact factor: 22.682
  3 in total
  2 in total

1.  Inflammatory bowel disease and systemic AA amyloidosis.

Authors:  Prayman T Sattianayagam; Julian D Gillmore; Jennifer H Pinney; Simon D J Gibbs; Ashutosh D Wechalekar; Janet A Gilbertson; Dorota Rowczenio; Philip N Hawkins; Helen J Lachmann
Journal:  Dig Dis Sci       Date:  2013-01-31       Impact factor: 3.199

Review 2.  Management of cutaneous disorders related to inflammatory bowel disease.

Authors:  Zaira Pellicer; Jesus Manuel Santiago; Alejandro Rodriguez; Vicent Alonso; Rosario Antón; Marta Maia Bosca
Journal:  Ann Gastroenterol       Date:  2012
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.